Clinuvel Pharmaceuticals Limited (CUVL) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Clinuvel Pharmaceuticals Limited (CUVL) closed at USD 5.30 on 2026-10-14, a change of -28.4 % over the past year, with a market capitalization of USD 255.46M.

Clinuvel Pharmaceuticals Limited recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Clinuvel Pharmaceuticals Limited key figures

Previous close

USD 5.30 (2026-10-14)

1-year change

-28.4 %

Market cap

USD 255.46M

Enterprise value

USD 5.05M

P/E ratio (trailing)

12.05

P/E ratio (forward)

n/a

EPS (trailing)

0.42

EPS (forward)

n/a

PEG ratio

n/a

Price to book

1.34

Revenue growth

-3.8 %

Earnings growth

5.3 %

Dividend per share (trailing)

0.05

Short ratio

0.54

Employees

n/a

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Clinuvel Pharmaceuticals Limited

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering therapies for patients with genetic, metabolic, and dermatological disorders in Australia, Ireland, the United States, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders; SCENESSE and other formulations of afamelanotide to treat severe disorders, including vitiligo and porphyrias; and pharmaceutical formulations melanocortin technology for the treatment of a range of disorders. In addition, the company provides photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. The company was incorporated in 1999 and is headquartered in Melbourne, Australia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Clinuvel Pharmaceuticals Limited and compare it with other stocks.